Plus   Neg

Reckitt Benckiser Says Indivior Indictment Not Against Group

Reckitt Benckiser Group PLC (RBGPF.PK,RB.L) noted the 9 April 2019 indictment by the US Justice Department in relation to Indivior Plc and Indivior Inc, the pharmaceuticals business which was demerged from RB at the end of 2014. Reckitt Benckiser said that the indictment is not against RB Group Plc or any other group company.

Indivior is accused of using fraudulent methods to increase sales. Indivior maintained that the accusations relate to events that occurred while it was still part of its former parent company.

RB Group said the indictment is not against RB Group Plc or any other group company and it currently has no additional or new information in respect of this matter, apart from what has been publicly issued by the Department of Justice and Indivior Plc.

In the indictment, the U.S. Justice Department accused Indivior of setting up a telephone and online program intended to connect callers with doctors that Indivior knew were prescribing Suboxone or opioids in a "careless and clinically unwarranted manner."

The Justice Department is seeking at least $3 billion and control of other property from Indivior. The drug-maker, which became a standalone business in 2014, denied the charges.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT